<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39468063</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2059-0105</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>28</Day></PubDate></JournalIssue><Title>NPJ vaccines</Title><ISOAbbreviation>NPJ Vaccines</ISOAbbreviation></Journal><ArticleTitle>mRNA COVID-19 vaccinations are not associated with RVO development 21 days and 12 weeks after vaccination.</ArticleTitle><Pagination><StartPage>202</StartPage><MedlinePgn>202</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41541-024-00983-0</ELocationID><Abstract><AbstractText>Case reports have speculated if COVID-19 vaccinations may be associated with retinal vascular occlusions (RVO). Specifically, previous literature speculated an increased risk of RVOs days to weeks after vaccination. After reviewing two recent analyses, mRNA COVID-19 vaccinations do not appear to increase the risk of RVOs at 3 and 12 weeks post-vaccination. Although both studies had different designs, mRNA vaccines do not appear to influence the risk of RVO development.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shaia</LastName><ForeName>Jacqueline K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Case Western School of Medicine Department of Population and Quantitative Health Sciences, Cleveland, OH, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Ophthalmic Bioinformatics Cleveland Clinic, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shukla</LastName><ForeName>Priya</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Center for Ophthalmic Bioinformatics Cleveland Clinic, Cleveland, OH, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jampol</LastName><ForeName>Lee</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Rishi P</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>Center for Ophthalmic Bioinformatics Cleveland Clinic, Cleveland, OH, USA. SINGHR@ccf.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cleveland Clinic Martin Hospitals, Stuart , Florida , USA. SINGHR@ccf.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30EY025585</GrantID><Agency>Research to Prevent Blindness (RPB)</Agency><Country /></Grant><Grant><GrantID>T32 EY024236</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>NPJ Vaccines</MedlineTA><NlmUniqueID>101699863</NlmUniqueID><ISSNLinking>2059-0105</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>29</Day><Hour>0</Hour><Minute>38</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39468063</ArticleId><ArticleId IdType="doi">10.1038/s41541-024-00983-0</ArticleId><ArticleId IdType="pii">10.1038/s41541-024-00983-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dorney, I., Shaia, J., Kaelber, D. C., Talcott, K. E. &amp; Singh, R. P. Risk of new retinal vascular occlusion after mRNA COVID-19 vaccination within aggregated electronic health record data. JAMA Ophthalmol. 141, 441–447 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaophthalmol.2023.0610</ArticleId><ArticleId IdType="pubmed">37052897</ArticleId><ArticleId IdType="pmc">10102921</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, J. X. et al. Risk assessment of retinal vascular occlusion after COVID-19 vaccination. NPJ Vaccines 8, 64 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-023-00661-7</ArticleId><ArticleId IdType="pubmed">37130882</ArticleId><ArticleId IdType="pmc">10153772</ArticleId></ArticleIdList></Reference><Reference><Citation>Vujosevic, S. et al. Retinal vascular occlusion and SARS-CoV-2 vaccination. Graefe’s Arch. Clin. Exp. Ophthalmol. 1, 3 (2022).</Citation></Reference><Reference><Citation>Cheng, J. Y. &amp; Margo, C. E. Ocular adverse events following vaccination: overview and update. Surv. Ophthalmol. 67, 293–306 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.survophthal.2021.04.001</ArticleId><ArticleId IdType="pubmed">33865883</ArticleId></ArticleIdList></Reference><Reference><Citation>Jampol, L. M. &amp; Maguire, M. G. No red flags for risk of retinal vascular occlusion after mRNA COVID-19 vaccination. JAMA Ophthalmol. 141, 447–448 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaophthalmol.2023.0925</ArticleId><ArticleId IdType="pubmed">37052902</ArticleId></ArticleIdList></Reference><Reference><Citation>National Center for Immunization and Respiratory Diseases (NCIRD). Division of Viral Diseases. Estimated COVID-19 Burden. https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/burden.html (2022).</Citation></Reference><Reference><Citation>Menter, T. et al. Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction. Histopathology 77, 198–209 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/his.14134</ArticleId><ArticleId IdType="pubmed">32364264</ArticleId><ArticleId IdType="pmc">7496150</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>